Form 4: Athira Pharma Director Grant Pickering Acquires Stock Options

Director Grant Pickering acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024, according to a Form 4 filing.

Summary

• Grant Pickering, a director of Athira Pharma, Inc., acquired 20,900 stock options on May 24, 2024.
• The exercise price of these options is $2.64.
• The options vest on the earlier of May 24, 2025, or the day before the next annual meeting of the Issuer's stockholders after May 24, 2024.
• The options expire on May 23, 2034.
• Following the transaction, Pickering directly owns 20,900 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• Shareholders may view the director's acquisition of stock options as a positive sign, indicating confidence in the company's future prospects.

Key Dates